Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers
|
By LabMedica International staff writers Posted on 29 Nov 2021 |

Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)
Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics of maternal inflammation and vascular etiologies.
The maternal pathophysiology impacts fetal physiology through the filter of the placenta. Triggers of the fetal inflammatory response are not completely understood, as there is contradictory evidence as to whether cytokines directly cross the placenta-blood barrier and emerge on the fetal side or if the fetal inflammatory response is indirectly triggered.
Clinical Scientists at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a prospective inceptional cohort study of preterm preeclampsia from July 1, 2010, through June 30, 2012. Eighty-one maternal-newborn dyads were examined. Placentas were analyzed for inflammatory and vascular pathologies. Neurodevelopmental assessment of infants utilizing the Pediatric Stroke Outcome Measure (PSOM) was conducted at 6-month corrected gestational age.
Maternal venous blood samples were collected at time of enrollment and within two hours after delivery. Fetal cord blood venous samples were obtained immediately after delivery by trained perinatal nurses with experience in venous cord blood collection. Platelet-poor plasma was aliquoted, frozen, and sent for cytokine analysis (IL-1β, IL-6, IL-8, and TNF-α) via the Luminex multicode assay platform (Luminex Corp, Austin, TX, USA). Placenta analysis assessments were conducted by a placental pathologist.
The investigators reported that worse neurological outcomes were not associated with elevated maternal / fetal cytokines. Early preterm birth (gestational age ≤ 32 weeks) was associated with worse neurological outcomes at 6-months regardless of maternal/ fetal cytokine levels, placental pathology, or cranial ultrasound findings (OR 1.70). When correcting for gestational age, elevated IL-6 approached significance as a predictor for worse developmental outcome (OR 1.025 ). Pathological evidence of maternal malperfusion and worse outcomes were noted in early preterm, although the sample size was small. When chronic villitis was present (N = 5), higher maternal levels of IL-6 (N = 3; 60%) were usually present rather than in fetal cord blood. Although only three cases of histologic fetal inflammatory response were seen, both IL-6 and IL-8 were elevated in the fetal cord blood (N = 2; 67%), but not elevated in maternal samples.
The authors concluded that their study supports the distinction that 32-weeks gestational age (‘moderate preterm) is a turning point for improved neurological outcomes. They found that cranial ultrasounds were unhelpful in predicting risk in this pre-eclamptic population. The data suggest that maternal placental malperfusion at earlier gestational age may be an underlying factor associated with poor neurological outcomes, although more robust studies are warranted. Neither elevated cytokines nor “male disadvantage” was associated with adverse neurological outcomes. The study was published on November 15, 2021 in the journal PloS One.
Related Links:
University of Colorado Anschutz Medical Campus
Luminex Corp
The maternal pathophysiology impacts fetal physiology through the filter of the placenta. Triggers of the fetal inflammatory response are not completely understood, as there is contradictory evidence as to whether cytokines directly cross the placenta-blood barrier and emerge on the fetal side or if the fetal inflammatory response is indirectly triggered.
Clinical Scientists at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a prospective inceptional cohort study of preterm preeclampsia from July 1, 2010, through June 30, 2012. Eighty-one maternal-newborn dyads were examined. Placentas were analyzed for inflammatory and vascular pathologies. Neurodevelopmental assessment of infants utilizing the Pediatric Stroke Outcome Measure (PSOM) was conducted at 6-month corrected gestational age.
Maternal venous blood samples were collected at time of enrollment and within two hours after delivery. Fetal cord blood venous samples were obtained immediately after delivery by trained perinatal nurses with experience in venous cord blood collection. Platelet-poor plasma was aliquoted, frozen, and sent for cytokine analysis (IL-1β, IL-6, IL-8, and TNF-α) via the Luminex multicode assay platform (Luminex Corp, Austin, TX, USA). Placenta analysis assessments were conducted by a placental pathologist.
The investigators reported that worse neurological outcomes were not associated with elevated maternal / fetal cytokines. Early preterm birth (gestational age ≤ 32 weeks) was associated with worse neurological outcomes at 6-months regardless of maternal/ fetal cytokine levels, placental pathology, or cranial ultrasound findings (OR 1.70). When correcting for gestational age, elevated IL-6 approached significance as a predictor for worse developmental outcome (OR 1.025 ). Pathological evidence of maternal malperfusion and worse outcomes were noted in early preterm, although the sample size was small. When chronic villitis was present (N = 5), higher maternal levels of IL-6 (N = 3; 60%) were usually present rather than in fetal cord blood. Although only three cases of histologic fetal inflammatory response were seen, both IL-6 and IL-8 were elevated in the fetal cord blood (N = 2; 67%), but not elevated in maternal samples.
The authors concluded that their study supports the distinction that 32-weeks gestational age (‘moderate preterm) is a turning point for improved neurological outcomes. They found that cranial ultrasounds were unhelpful in predicting risk in this pre-eclamptic population. The data suggest that maternal placental malperfusion at earlier gestational age may be an underlying factor associated with poor neurological outcomes, although more robust studies are warranted. Neither elevated cytokines nor “male disadvantage” was associated with adverse neurological outcomes. The study was published on November 15, 2021 in the journal PloS One.
Related Links:
University of Colorado Anschutz Medical Campus
Luminex Corp
Latest Immunology News
- New Cellular Map May Help Predict Crohn’s Disease Course in Children
- Temporal Immune Profiling Reveals How Sepsis States Change Over Time
- Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
- Gut “Memory” May Explain Why IBD Flares Return
- AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
- Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
- Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
- Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
- Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
- Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
- Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
- New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
- Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
- Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
- Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
- Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Channels
Clinical Chemistry
view channel
International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more
Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening
Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read moreMolecular Diagnostics
view channel
Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
Predicting when Alzheimer’s disease will manifest remains a major clinical challenge, particularly before cognitive decline is evident. Blood biomarkers and genetic risk markers can flag elevated risk,... Read more
Blood Protein Analysis Helps Interpret Uncertain Rare Disease Variants
Many patients with suspected rare genetic conditions remain undiagnosed even after genome or exome sequencing, leaving clinicians with limited evidence to interpret uncertain variants. Variants of uncertain... Read moreHematology
view channel
Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
Immune-mediated thrombosis following heparin therapy can be sudden and severe, creating urgent diagnostic challenges. In heparin-induced thrombocytopenia (HIT), antibodies against platelet factor 4 (PF4)... Read more
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read moreMicrobiology
view channel
Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
Hospitals face persistent pressure to improve diagnostic accuracy while reducing unnecessary testing and costs. Misordered or overused assays can complicate infection metrics, trigger penalties, and strain... Read more
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read morePathology
view channel
AI Spatial Analysis of Routine Slides Helps Predict Pancreatic Cancer Recurrence
Predicting which patients with pancreatic cancer will recur after treatment and surgery remains challenging. Pathology evaluation typically measures residual tumor burden, but recent work found that tumor... Read more
Hybrid Computational Imaging Method Improves Digital Pathology Resolution
Digital pathology depends on high-resolution whole-slide imaging to capture diagnostically relevant cellular and tissue features, yet conventional methods often force trade-offs between speed, cost, and detail.... Read moreTechnology
view channel
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Blood-Based Neurology Biomarker Assays Authorized for Use in Brazil
H.U. Group Holdings Inc. (Tokyo, Japan) and its wholly owned subsidiary Fujirebio announced that the Brazilian Health Regulatory Agency (ANVISA) has authorized the Lumipulse G NfL Blood and Lumipulse G... Read more







